|
Unipolar Depression
|
0.310 |
Biomarker
|
disease |
BEFREE |
It has been reported that NTM might play a role in late-onset Alzheimer disease while NR3C2 may be associated with cognitive function and major depression.
|
21036197 |
2011 |
|
Major Depressive Disorder
|
0.310 |
Biomarker
|
disease |
BEFREE |
It has been reported that NTM might play a role in late-onset Alzheimer disease while NR3C2 may be associated with cognitive function and major depression.
|
21036197 |
2011 |
|
Tuberculosis
|
0.080 |
Biomarker
|
disease |
BEFREE |
These include GenoType MTBDRplus Version 2.0 (Hain Lifescience), Xpert® MTB/RIF (Cepheid) and Anyplex™ plus MTB/NTM/DR-TB Real-time detection (Seegene).
|
26553046 |
2015 |
|
Tuberculosis
|
0.080 |
Biomarker
|
disease |
BEFREE |
We evaluated the quantitative capability of the AdvanSure TB/NTM real-time PCR kit (LG Life Science, Korea) to determine the cycle threshold (Ct) for mycobacterial burden.
|
24422196 |
2014 |
|
Tuberculosis
|
0.080 |
Biomarker
|
disease |
BEFREE |
Compared to culture, the sensitivity in the selected smear-positive specimens was 0.91 (0.92 for MTC and 0.90 for NTM), and there was no molecular detection of NTM in a tuberculosis case or vice versa.
|
23100355 |
2013 |
|
Tuberculosis
|
0.080 |
Biomarker
|
disease |
BEFREE |
Moreover, the NTM-CPA group was more likely to have a history of tuberculosis and chronic obstructive lung disease and to have used inhaled or systemic steroids.
|
29190796 |
2017 |
|
Tuberculosis
|
0.080 |
Biomarker
|
disease |
BEFREE |
Comparison of AdvanSure TB/NTM PCR and COBAS TaqMan MTB PCR for Detection of Mycobacterium tuberculosis Complex in Routine Clinical Practice.
|
25932446 |
2015 |
|
Tuberculosis
|
0.080 |
Biomarker
|
disease |
BEFREE |
In Queensland, Australia, all cases of mycobacterial infection (tuberculosis [TB] and nontuberculous mycobacteria [NTM]) are notifiable under the Queensland Public Health Act (2005).
|
28118021 |
2017 |
|
Tuberculosis
|
0.080 |
Biomarker
|
disease |
BEFREE |
We estimated odds ratios comparing ICS use with nonuse among NTM-PD and TB cases and controls using conditional logistic regression.Among 417 494 older adults with treated obstructive lung disease, we identified 2966 cases of NTM-PD and 327 cases of TB.
|
28931659 |
2017 |
|
Tuberculosis
|
0.080 |
GeneticVariation
|
disease |
BEFREE |
Regarding the age distribution, the greatest increases were observed in patients over 75 years for TB and in patients 50-74 years for NTM.
|
31128614 |
2019 |
|
Lymphadenitis
|
0.030 |
Biomarker
|
disease |
BEFREE |
The objective was to describe the characteristics of hearing losses documented in patients treated with clarithromycin alone for nontuberculous mycobacterial NTM lymphadenitis in a pediatric tertiary care center over a 12-year period.
|
30032669 |
2018 |
|
Lymphadenitis
|
0.030 |
Biomarker
|
disease |
BEFREE |
NTM commonly cause one of five different clinical syndromes: pleuropulmonary disease, skin and soft tissue infection, osteoarticular infection, disseminated disease, including that caused by catheter-associated infection, and lymphadenitis.
|
31077618 |
2019 |
|
Lymphadenitis
|
0.030 |
Biomarker
|
disease |
BEFREE |
Contact with other farm animals was not associated to NTM lymphadenitis.
|
28265761 |
2017 |
|
Bronchiectasis
|
0.020 |
Biomarker
|
disease |
BEFREE |
Patients with NTM were older, predominantly women, and had bronchiectasis diagnosed at a later age than those without NTM.
|
27889361 |
2017 |
|
Bronchiectasis
|
0.020 |
Biomarker
|
disease |
BEFREE |
The stakeholder panel consisted of clinical research experts in bronchiectasis, a seven-member patient advisory panel, and representatives from the two key patient advocacy organizations: COPD Foundation and NTM Info and Research Inc. Based on survey results from 459 patients with bronchiectasis, the stakeholder panel identified 27 patient-centered research priorities for bronchiectasis in the areas of bronchiectasis treatment and prevention of exacerbations, improving treatment of exacerbations and infections, improving health-related quality of life, predictors of poor prognosis, understanding the impact of underlying conditions, and conducting patient-centered clinical trials.
|
29981718 |
2018 |
|
Lung diseases
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Of the 23 patients who successfully completed treatment, 11 (48%) redeveloped NTM lung disease, with mycobacterial genotyping results indicating that the majority of cases were due to reinfection.
|
30104265 |
2018 |
|
Lung diseases
|
0.020 |
GeneticVariation
|
group |
BEFREE |
While underlying lung disease is a well-established risk factor for NTM-PD, it may also occur in apparently healthy individuals.
|
31221809 |
2019 |
|
Mycobacterium avium-intracellulare Infection
|
0.020 |
Biomarker
|
disease |
BEFREE |
The most common causative organism for NTM was Mycobacterium avium complex (87.3%), M. abscessus complex (5.5%) and M. kansasii (3.9%).
|
31128614 |
2019 |
|
Mycobacterium avium-intracellulare Infection
|
0.020 |
Biomarker
|
disease |
BEFREE |
The most frequently isolated NTM were MAC (46%).
|
28787454 |
2017 |
|
Neoplasms
|
0.020 |
AlteredExpression
|
group |
BEFREE |
OPCML, LSAMP and NEGR1 exhibited reduced expression in the tumor samples relative to the normal samples, whereas HNT expression was elevated.
|
16115914 |
2005 |
|
Neoplasms
|
0.020 |
Biomarker
|
group |
BEFREE |
Seventy-nine patients had NTM-RFA and 62 had SR. After IPTW, the two groups were well-balanced for most baseline characteristics including tumor size, location, etiology, severity of underlying liver disease and alpha-fetoprotein level.
|
29410287 |
2018 |
|
Tuberculosis, Pulmonary
|
0.020 |
Biomarker
|
disease |
BEFREE |
Molecular misidentification of NTM cases occurred when testing 2 gastric aspirates from two children with clinically but not microbiologically confirmed lung tuberculosis.
|
23100355 |
2013 |
|
Tuberculosis, Pulmonary
|
0.020 |
Biomarker
|
disease |
BEFREE |
The Xpert MTB/RIF and TB/NTM PCR assay in bronchial washing specimens can improve the diagnostic yields for PTB, although there were considerable discordant results without any patient-related risk factors.
|
27760181 |
2016 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
Together these data support a role for NTM and OPCML in developmental delay and potentially in cancer susceptibility.
|
23495067 |
2013 |
|
Intracranial Aneurysm
|
0.010 |
Biomarker
|
disease |
BEFREE |
After application of a genome-wide paired-end DNA sequencing method for breakpoint mapping, we demonstrate that this translocation breaks intron 1 of a splicing isoform of Neurotrimin at 11q25 in a previously implicated candidate region for IAs and AAs (OMIM 612161).
|
23054244 |
2012 |